Gilead Stands Its Ground With Harvoni: HCV Price War Less Likely
Executive Summary
Firm makes clear that pricing of Harvoni is meant to match the cost of Sovaldi plus the interferon/ribavirin therapeutic backbone. Despite stakeholder criticism, Wall Street expects Gilead’s competitors will not attempt to compete via price.
You may also be interested in...
Gilead Gets Positive EU Opinion On Proprietary HCV Combo Pill Harvoni
Europe’s top scientific advisory panel has cleared for approval Gilead’s new hepatitis C antiviral combination of sofosbuvir plus ledipasvir, as well as Almirall’s new inhaled combo of aclidinium and formoterol and AstraZeneca’s new constipation therapy naloxegol.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.